Last reviewed · How we verify
NCT07045181
Prediction Model of Pancreatic Neoplasms in CP Patients With Focal Pancreatic Lesions
trial testing XGBoost machine learning in Chronic Pancreatitis in 113 participants. Completed in 5 August 2025.
1 August 2025
Quick facts
| Lead sponsor | Changhai Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 113 |
| Start date | 1 July 2025 |
| Primary completion | 1 August 2025 |
| Estimated completion | 5 August 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- XGBoost machine learning
Conditions studied
- Chronic Pancreatitis — all drugs for Chronic Pancreatitis →
- Pancreatic Neoplasm — all drugs for Pancreatic Neoplasm →
- Machine Learning — all drugs for Machine Learning →
Sponsor
Changhai Hospital
Who can join
Eligibility, any sex, with Chronic Pancreatitis or Pancreatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to develop XGBoost machine learning model to predict pancreatic neoplasms in CP patients with focal pancreatic lesions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07045181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Pancreatitis
Currently open trials in the same condition.
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT06655051 — Single Plastic Stent Vs. Fully Covered Self-Expanding Metal Stent on Benign Biliary Stricture Secondary to Chronic Pancr · NA · recruiting
- NCT06937294 — Metformin in Post Chronic Pancreatitis Diabetes Mellitus · Phase 4 · recruiting
- NCT07109180 — Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOT · NA · recruiting
- NCT06925204 — Natural Course and Therapeutic Effect of Chronic Pancreatitis · recruiting
Other Changhai Hospital trials
Trials by the same sponsor.
- NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
- NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07045181 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
- Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07045181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing